| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (NCT04981509) | National Cancer Institute (NCI) | 2022-06-10 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer (NCT05012371) | M.D. Anderson Cancer Center | 2022-02-16 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (NCT05122546) | City of Hope Medical Center | 2021-11-01 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040) | M.D. Anderson Cancer Center | 2021-04-14 |
| Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery (NCT04370509) | University of California, San Francisco | 2021-02-09 |
| Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma (NCT04393350) | Emory University | 2020-06-22 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes (NCT04501913) | City of Hope Medical Center | 2019-12-24 |
| Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer (NCT04022343) | Emory University | 2019-08-06 |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (NCT03793166) | National Cancer Institute (NCI) | 2019-06-07 |
| CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (NCT03829111) | City of Hope Medical Center | 2019-05-14 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385) | National Cancer Institute (NCI) | 2019-01-29 |
| A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (NCT03595124) | National Cancer Institute (NCI) | 2019-01-08 |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (NCT03587662) | M.D. Anderson Cancer Center | 2018-08-17 |
| Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT03334409) | Academic and Community Cancer Research United | 2018-02-16 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208) | National Cancer Institute (NCI) | 2015-07-22 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |